ANZCTR search results

Research has revealed that 50% - 60% of individuals do not seek help prior to a suicide attempt, thus it is imperative we find new ways to reach them. One way to reach them is to use a Google Ads campaign, in which a person visiting the website is asked if they have previously sought help before, with the intention of providing more relevant offerings. In this study, we assess the impact of reducing the effort needed by individuals to seek help on help seeking.

Heart failure with preserved ejection fraction (HFpEF) is the most prevalent phenotype of heart failure. However, the treatment options for these patients remain limited. Permanent pacemakers are commonly used in the management of bradycardia (low heart rate), with many pacemaker patients also presenting with early HFpEF. This study is a prospective, two-arm randomised controlled trial including 160 participants with pacemakers and early HFpEF from Adelaide, South Australia. Participants will be randomised to an accelerated pacing rate (75bpm) or usual care (60bpm), performing follow-up at 4-weeks and 52-weeks post randomisation. It is hypothesised that increasing the heart rate settings compared to standard permanent pacemaker settings, will improve exercise tolerance, defined using peak oxygen consumption, at 12-months post-randomisation.

OM002 is a synthetic oligosaccharide that is identical to the human milk oligosaccharide (HMO) 2’ fucosyllactose (2'FL) and has the potential to address the underlying pathophysiology of Parkinson’s Disease (PD) constipation and address unmet clinical needs in these patients. This study is being conducted to assess the safety and efficacy of OM002 relating to reduced severity of constipation and disease progression in patients with PD. This double-blind, randomized, placebo-controlled study trial will consist of two groups (n=80/each) who will receive either OM002 or placebo for 13 weeks in addition to the standard of care. Following this period both groups will receive an open-label for an additional 13 weeks. Biological samples and surveys will be sampled at 5 time points (baseline, mid-treatment, completion of first arm (13 weeks), mid-open-label treatment, and at the end of the open-label treatment period (13 weeks)). Trial data will be used in combination with available open-label data to guide the late-stage development of OM002 in participants with PD. We hypothesise that ingestion of 10 grams of OM002 daily will improve cognitive function and reduce GI symptom severity in patients diagnosed with PD.

This study is aiming to evaluate the efficacy of an interactive online portal, iCare, in improving the health and wellbeing of people living with complex cancers, and their informal carers. Who is it for? You may be eligible for this study if you are an adult who has been diagnosed with an upper gastrointestinal (GI) cancer in the past 3 months, or a carer who is looking after someone who has been diagnosed with an upper GI cancer. Study details Patients and carers will be provided access to the online iCare platform as often as they would like over a three month period. The platform will provide information on the patient journey, support and resources with a facility to identify and record medical symptoms. All participants will be asked to complete surveys at baseline, 3-months and 6-months post-recruitment. It is hoped that findings from this study will help determine the utility of the iCare platform in supporting the emotional needs of complex cancer patients and their carers.

Glucose-dependent insulinotropic polypeptide (GIP) is a natural hormone released from the intestines after meals. It regulates blood sugar levels by controlling insulin secretion. Our recent studies suggest it may also regulate glucose excretion in the urine. We want to find out whether giving an intravenous infusion of GIP can affect urinary glucose excretion in people with type 2 diabetes.

This study aims to assess the effectiveness, cost-effectiveness, and implementation context of an integrated liver fibrosis detection pathway in detecting unrecognized advanced liver fibrosis in at-risk patients in primary care. Who is it for? You may be eligible to participate in this trial if you are between 45-75 years and are at risk of chronic liver disease and are under the care of a GP at a participating general practice clinic, Study details GP clinics will be randomised to one of two cluster groups. One group will receive usual care provided by their GP. The other group will have a liver fibrosis detection pathway implemented through the Future Health Today (FHT) clinical decision support system (CDSS). GPs will be alerted by the CDSS from the electronic patient medical record if their patient is at-risk for advanced liver fibrosis and warrant further investigation. Further investigation will be prompted by way of a screening blood test for liver fibrosis and then a diagnostic special liver ultrasound, known as a liver elastogram. It is hoped that this research will demonstrate if this clinical decision support system is effective in improving detection of liver disease and liver cancer, thus improving patient outcomes.

This study evaluates a lifestyle program that aims to improve quality of life in young people who are recovering from cancer treatment. Who is it for? You are eligible for this study if you are aged between 15-25 years of age and have either completed intensive treatment (surgery, chemotherapy and radiotherapy) or are on maintenance therapy for any cancer diagnosis. Study details Participants will receive access to online lifestyle modules to work through over eight weeks, as well as three individual one-hour consultations with Canteen staff (cancer nurses, psychologists and social workers) to discuss how to identify and meet their wellbeing needs. Participants will also be asked to complete questionnaires on their physical and mental health status. It is hoped that findings from this study will help develop programs to ensure young people who survive cancer have the same quality of life as young people who haven’t had cancer.

Deferred (delayed) cord clamping for at least 60 seconds improves survival in very preterm infants. However, some infants require positive pressure ventilation to establish breathing in the first minutes after birth. For these infants, the cord is often clamped early, therefore they miss out on the benefits of deferred cord clamping. Furthermore, positive pressure ventilation may injure the fragile preterm lung. Nasal high-flow therapy (nasal high-flow) provides heated, humidified, blended air and oxygen via two small nasal prongs. We hypothesise that the provision of nasal high-flow prior to cord clamping may support and stimulate breathing, therefore allowing deferred cord clamping to occur and limiting positive pressure ventilation, improving outcomes. In this single-centre pilot feasibility trial, preterm infants born 26-31+6 weeks’ gestation will receive nasal high-flow during deferred cord clamping. We aim to study the feasibility of providing nasal high-flow prior to cord clamping in 20 infants with respect to 1) acceptability to clinicians and 2) practical application. We will also study clinical and physiological outcomes in infants receiving nasal high-flow during deferred cord clamping. These pilot data will help establish feasibility for a larger randomised controlled trial, and inform the primary outcome and sample size for this definitive trial.

This is a randomized, placebo-controlled, sequential, participant- and Investigator-masked Phase 1 study to assess the safety, tolerability, PK, and PD of ascending single and multiple doses of SAR446422 in female and male healthy participants 18 to 55 years of age. Number of participants: Up to 120 participants will be randomized to study intervention at a single study site. Part1-SAD17875: approximately 9 dose level cohorts with 8 participants per cohort (6 active and 2 placebo). The last cohort will be optional. Part2-MAD17876: approximately 4 dose level cohorts with 12 participants per cohort (9 active and 3 placebo). The last cohort will be optional.

Researchers at the Centre for Eye Research Australia (CERA) in collaboration with industry partner Eyetelligence Pty Ltd have developed a system integrating retinal photography and artificial intelligence (AI) to predict the risk of heart diseases. The retina is located at the back of the eye and has the important ability to sense vision. When the retina is photographed, it shows small vessels that can indicate the health of your heart. The cardiovascular disease (CVD) risk score refers to the probability of developing CVD events in the future. This project aims to assess the real-world impact, accuracy, and feasibility of the rpCVD screening system in primary care settings in Australia.